Overview

Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation

Status:
Withdrawn
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Patients undergoing living donor renal transplant will be asked to participate to determine whether pre-operative dosing of immunosuppressive medication, and the donor organ receiving an additional dose of antibody induction therapy helps to alleviate potential damage to the transplanted organ post-transplant. A number of lab tests will be done post-transplant to determine how well the kidney is functioning.
Phase:
Phase 4
Details
Lead Sponsor:
Georgetown University
Collaborator:
Novartis
Treatments:
Antilymphocyte Serum
Mycophenolate mofetil
Mycophenolic Acid
Thymoglobulin